CHIEF & AST/ASO/FULL PROF

• An MD or equivalent medical degree, with appropriate specialty qualifications in hematology and/or medical oncology.
• A distinguished record as a physician-investigator, including significant peer-reviewed scholarship and sustained NIH or equivalent extramural funding as an independent investigator.
• An active research program and a clear commitment to maintaining extramural research support while serving as Chief.
• Evidence of effective leadership, program development, building and retaining high-performing teams, fostering a positive work environment, and multidisciplinary collaboration.
• A strong commitment to clinical excellence, education, and the career development of faculty and trainees.
• Academic accomplishments appropriate for appointment at the Associate Professor or Professor level.

The Division and Research Environment
The Division of Hematology & Oncology at the University of Florida is a leading academic division dedicated to advancing the prevention, diagnosis, and treatment of cancer and blood disorders through exceptional patient care, innovative research, and outstanding medical education. Supported by more than 40 clinical faculty members and 15 fellows, the Division encompasses three clinical programs: Medical Oncology, Classical Hematology, and Hematologic Malignancy, Transplant and Cellular Therapy. With a commitment to academic excellence and multidisciplinary collaboration, the Division is dedicated to advancing clinical practice, scientific discovery, and the next generation of leaders in hematology and oncology.

The Division provides comprehensive inpatient and outpatient services spanning a broad spectrum of solid tumors, benign and malignant blood disorders, and complex hematologic malignancies, including advanced transplant and cellular therapies. Its Hematologic Malignancy, Transplant and Cellular Therapy program recently achieved reaccreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) across all aspects of the program. The Division also maintains a strong commitment to education and mentorship, with an expanding fellowship program that will introduce a Medical Scientist Training Program (MSTP) fellowship in FY28 to further advance physician-scientist development and translational research.

Division faculty lead and participate in clinical and translational research spanning solid tumors, hematologic malignancies, transplantation, and cellular therapy. Through their research efforts and collaboration with the UF Health Cancer Institute (UFHCI), faculty contribute to the advancement of cancer care and the development of innovative treatments. Across UFHCI, nearly 1,000 subjects are enrolled annually in interventional cancer clinical trials, reflecting the broader institute’s clinical research enterprise and providing opportunities for multidisciplinary investigation and the translation of scientific discoveries into improved patient outcomes.

Cancer-focused faculty in the UF Division of Hematology & Oncology are members of the University of Florida Health Cancer Institute (UFHCI), Florida’s only National Cancer Institute (NCI) designated cancer institute based at a public university. UFHCI integrates comprehensive patient care and innovative research in a collaborative, multidisciplinary environment, with members representing all 16 colleges at the University of Florida. The University of Florida is ranked No. 8 among public universities by U.S. News & World Report in its 2027 rankings and No. 9 among public universities by Forbes in its 2027 rankings, reflecting its standing as a premier public research institution committed to discovery, innovation, and academic excellence.

Institutional Environment
The University of Florida is a Top‑10 public research university with six health colleges, numerous centers and institutes, and an integrated academic health center that supports collaborative care and discovery across the continuum of medicine. UF Health Shands Hospital is a large quaternary referral hospital with multiple nationally ranked specialties and a broad catchment area. Faculty benefit from a rich research ecosystem, including an NIH Clinical and Translational Science Institute and multiple disease-focused centers, as well as strong graduate and postdoctoral training programs.

Compensation and Application
UF offers a competitive compensation plan with opportunities for incentive earnings, university-paid health, life, and long‑term disability insurance, retirement programs with employer contribution, professional liability protection, and relocation assistance. Academic rank and track will be commensurate with experience and qualifications.

Interested applicants should submit a curriculum vitae and cover letter to careers@medicine.ufl.edu. The cover letter should describe the candidate’s research accomplishments and funding history, leadership and mentoring experience, and vision for building a Division with a growing, collaborative program of NIH-funded investigators.

Key Responsibilities
1. Establish and implement a strategic vision that advances the Division’s research, clinical, educational, and faculty development missions.
2. Build and grow a program of NIH-funded investigators through targeted recruitment, retention, mentorship, and development of current and recruited faculty, while proactively assessing workforce needs to support the Division's clinical and academic missions.
3. Maintain an active, independently funded research program supported by sustained NIH or equivalent peer-reviewed extramural funding.
4. Partner with UF Health Cancer Institute leadership to align recruitment and research priorities, develop collaborative programs, and expand opportunities for basic, translational, and clinical investigation.
5. Advance clinical programs in hematology and oncology, integrating high-quality patient care with clinical trials and investigator-initiated research, while providing leadership oversight to ensure program quality, operational sustainability, and continued accreditation readiness, including FACT.
6. Oversee and strengthen fellowship education and the Division’s contributions to resident, medical student, and research training.
7. Foster a collaborative environment that supports faculty achievement, academic advancement, and leadership development.
8. Provide effective administrative and fiscal stewardship, proactively identifying workforce and operational risks, advocating for necessary resources, and collaborating across the academic health system to address challenges and align divisional resources with strategic priorities.

Salary is negotiable, commensurate with education and experience.

Rank and Tenure status will be commensurate with qualifications.

• An MD or equivalent medical degree, with appropriate specialty qualifications in hematology and/or medical oncology.
• A distinguished record as a physician-investigator, including significant peer-reviewed scholarship and sustained NIH or equivalent extramural funding as an independent investigator.
• An active research program and a clear commitment to maintaining extramural research support while serving as Chief.
• Evidence of effective leadership, program development, building and retaining high-performing teams, fostering a positive work environment, and multidisciplinary collaboration.
• A strong commitment to clinical excellence, education, and the career development of faculty and trainees.
• Academic accomplishments appropriate for appointment at the Associate Professor or Professor level.

Please attach curriculum vitae and three letters of recommendation.

Final candidate will be required to provide official transcript to the hiring department upon hire. A transcript will not be considered "official" if a designation of "Issued to Student" is visible. Degrees earned from an education institution outside of the United States are required to be evaluated by a professional credentialing service provider approved by the National Association of Credential Evaluation Services (NACES), which can be found at http://www.naces.org/.

Application must be submitted by 11:55 p.m. (ET) of the posting end date.